Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

June 15, 2026 10:23 AM EDT PeopleR&D Neumo­ra drug fails two more Phase 3 tri­als, biotech to lay off 35% of staff Max Gelman Senior Editor The Re­al­ly Big Neu­ro­science Com­pa­ny is prov­ing to be a Re­al­ly Big Flop with each pass­ing up­date. Neumo­ra Ther­a­peu­tics will dis­con­tin­ue its lead de­pres­sion drug … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER